GDF6: A Promising Drug Target and Biomarker for Diseases (G392255)

Target Name: GDF6

NCBI ID: G392255

GDF6

Other Name(s): KFSL | BMP13 | GDF-6 | Bone morphogenetic protein 13 | growth differentiation factor 6 | SGM1 | bone morphogenetic protein 13 | BMP-13 | GDF6_HUMAN | growth/differentiation factor 16 | KFM | MGC158100 | Growth/differentiation factor 16 | Growth/differentiation factor 6 | Growth differentiation factor 6 | KFS | CDMP2 | KFS1 | SYNS4 | MGC158101

GDF6: A Promising Drug Target and Biomarker for Diseases

GDF6 (Glycophospholipidase A3) is a protein that is expressed in various tissues throughout the body, including the liver, muscle, and heart. It is a member of the family of phospholipase D (PLD) enzymes, which are involved in the breakdown of phospholipids in various cell types. One of the unique features of GDF6 is its ability to catalyze the hydrolysis of very long-chain phospholipids, such as those found in cell membranes. This ability makes it a promising drug target and a potential biomarker for a variety of diseases.

GDF6 has been shown to play a role in the regulation of various cellular processes, including cell signaling, inflammation, and stress responses. For example, GDF6 has been shown to be involved in the regulation of angiogenesis, the formation of new blood vessels, and the regulation of immune cell function. In addition, GDF6 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and inflammation.

GDF6 has also been shown to be involved in the regulation of inflammation and immune cell function. For example, GDF6 has been shown to play a role in the regulation of the production and activation of immune cells, such as T cells and natural killer cells. In addition, GDF6 has been shown to play a role in the regulation of the inflammatory response, by promoting the production of pro-inflammatory cytokines and activating the recruitment of immune cells to the site of inflammation.

In addition to its role in cellular signaling and inflammation, GDF6 has also been shown to be involved in the regulation of cellular processes related to energy metabolism. For example, GDF6 has been shown to play a role in the regulation of lipid metabolism, by breaking down very long-chain phospholipids and promoting the production of fatty acids. This ability to regulate lipid metabolism makes GDF6 a potential target for diseases related to energy metabolism, such as obesity and type 2 diabetes.

GDF6 has also been shown to play a role in the regulation of cellular processes related to cell death and stress responses. For example, GDF6 has been shown to play a role in the regulation of cell stress, by promoting the production of pro-inflammatory cytokines and activating the recruitment of immune cells to the site of cellular stress. This ability to regulate cell stress makes GDF6 a potential target for diseases related to cellular stress, such as neurodegenerative diseases and cancer.

GDF6 is also a potential biomarker for a variety of diseases, due to its ability to be targeted by small molecules and its involvement in the regulation of cellular processes that are relevant to a wide range of diseases. For example, GDF6 has been shown to be involved in the regulation of a variety of cellular processes that are relevant to a variety of diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. This makes GDF6 a potential target for the development of new therapies for these diseases.

In conclusion, GDF6 is a protein that is involved in a variety of cellular processes that are relevant to a wide range of diseases. Its ability to catalyze the hydrolysis of very long-chain phospholipids, as well as its involvement in the regulation of cellular signaling pathways, inflammation, energy metabolism, and cell death and stress responses, make it a promising drug target and a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of GDF6 in these processes and to develop new therapies for the treatment of diseases related to its dysfunction.

Protein Name: Growth Differentiation Factor 6

Functions: Growth factor that controls proliferation and cellular differentiation in the retina and bone formation. Plays a key role in regulating apoptosis during retinal development. Establishes dorsal-ventral positional information in the retina and controls the formation of the retinotectal map (PubMed:23307924). Required for normal formation of bones and joints in the limbs, skull, digits and axial skeleton. Plays a key role in establishing boundaries between skeletal elements during development. Regulation of GDF6 expression seems to be a mechanism for evolving species-specific changes in skeletal structures. Seems to positively regulate differentiation of chondrogenic tissue through the growth factor receptors subunits BMPR1A, BMPR1B, BMPR2 and ACVR2A, leading to the activation of SMAD1-SMAD5-SMAD8 complex. The regulation of chondrogenic differentiation is inhibited by NOG (PubMed:26643732). Also involved in the induction of adipogenesis from mesenchymal stem cells. This mechanism acts through the growth factor receptors subunits BMPR1A, BMPR2 and ACVR2A and the activation of SMAD1-SMAD5-SMAD8 complex and MAPK14/p38 (By similarity)

The "GDF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets